Efficacy of autoPPC for the Treatment of Obstructive Sleep Apnea Syndrome (OSAS)
Primary Purpose
Obstructive Sleep Apnea Syndrome
Status
Unknown status
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
autoPPC
Sponsored by
About this trial
This is an interventional treatment trial for Obstructive Sleep Apnea Syndrome
Eligibility Criteria
Inclusion Criteria:
- Patients with obstructive sleep apnea syndrome and indication for autoPPC
Exclusion Criteria:
- Patients with COPD, or evolutive heart disease Patients with evolutive cancer Patients already with PPC machine Patients simultaneously included in another clinical study.
Sites / Locations
- MEURICERecruiting
- Service explorations fonctionnelles - Hopital La Miletrie
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
autoPPC
Arm Description
Outcomes
Primary Outcome Measures
Residual sleep-related events .
Secondary Outcome Measures
Tolerance and confort of the autoPPC machine
Full Information
NCT ID
NCT00875680
First Posted
April 2, 2009
Last Updated
February 9, 2012
Sponsor
Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche
1. Study Identification
Unique Protocol Identification Number
NCT00875680
Brief Title
Efficacy of autoPPC for the Treatment of Obstructive Sleep Apnea Syndrome (OSAS)
Official Title
Evaluation of the Efficacy of Autoadjusted Positive Pressure Devices for the Treatment of Obstructive Sleep Apnea Syndrome
Study Type
Interventional
2. Study Status
Record Verification Date
February 2012
Overall Recruitment Status
Unknown status
Study Start Date
May 2009 (undefined)
Primary Completion Date
June 2011 (Actual)
Study Completion Date
June 2014 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Obstructive Sleep Apnea Syndrome (OSAS) is a common condition that leads to daytime sleepiness and loss of vigilance and, in addition, increased risk of cardiovascular events. The most effective treatment consists in ventilation by mask with continuous positive airway pressure (CPAP), that prevents collapse of the upper airway. However the degree of collapsibility of the pharynx may vary in relation to position, sleep stage, or alcohol or sedative consumption. Thus, CPAP treatment (invented in 1981) has evolved with the development of more sophisticated equipment that permits adapted variations in pressure levels (autoCPAP) with the objective adjusted pressure to avoid airways obstruction with minimal pressure.
Different models of autoCPAP function with different signals and event detection algorithms with different modes of reaction to events. These machines are marketed with CE certification, that guarantees electrical security, but there is to date, no requirement for pre-marketing clinical validation. Nonetheless inadequate treatment may leave patients at risk of accidents and cardiovascular events. These machines can be bench tested using test equipment that can measure with accuracy the response to simulated events, but the testing equipment cannot simulate the diversity of clinical situations, nor the residual level of microarousals that may persist. Thus these bench tests need to be supplemented by clinical studies. The investigators objective is to test the efficacy of these machines on residual sleep-related events during a one night autotitration polysomnography. We develop a prospective, multicentre, non randomised study with autotitration polysomnography only for one night. These clinical results will be compared with the results of bench tests in order to evaluate the pertinence of the bench tests and their eventual utility to simplify clinical evaluation. The perspective of developing a reliable testing protocol may eventually play a role in the certification of these machines.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obstructive Sleep Apnea Syndrome
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
20 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
autoPPC
Arm Type
Experimental
Intervention Type
Device
Intervention Name(s)
autoPPC
Intervention Description
To test the efficacy of autoPPC machines on residual sleep-related events during a one night autotitration polysomnography.
Primary Outcome Measure Information:
Title
Residual sleep-related events .
Time Frame
One night of polysomnography
Secondary Outcome Measure Information:
Title
Tolerance and confort of the autoPPC machine
Time Frame
one night
10. Eligibility
Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients with obstructive sleep apnea syndrome and indication for autoPPC
Exclusion Criteria:
Patients with COPD, or evolutive heart disease Patients with evolutive cancer Patients already with PPC machine Patients simultaneously included in another clinical study.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jean Claude MEURICE, Pr
Phone
05 49 44 43 87
Email
meurice@chu-poitiers.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jean Claude MEURICE, Pr
Organizational Affiliation
Service explorations fonctionnelles. Hopital La miletrie . POITIERS
Official's Role
Principal Investigator
Facility Information:
Facility Name
MEURICE
City
Poitiers
ZIP/Postal Code
86021
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jean Claude MEURICE
Phone
+33.5.49.44.43.87
Facility Name
Service explorations fonctionnelles - Hopital La Miletrie
City
Poitiers
ZIP/Postal Code
86021
Country
France
Individual Site Status
Active, not recruiting
12. IPD Sharing Statement
Learn more about this trial
Efficacy of autoPPC for the Treatment of Obstructive Sleep Apnea Syndrome (OSAS)
We'll reach out to this number within 24 hrs